Programmed Cell Death Protein 1/Programmed Cell Death Ligand 1 Signaling Pathway Mediated Interleukin-10 and Bacterial Biofilm Formation to Drug Resistance Mechanism of Pneumoniae Meningitis.

It aimed to explore the resistance and biofilm formation characteristics of pneumococcal meningitis (PM) and the mechanism of programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) signaling pathway (SPW). Firstly, the drug susceptibility test of 32 Streptococcus pneumoniae strains isolated from patients with PM and the biofilm semi-quantitative determination was performed. Then, the PM mouse model was constructed. The differences in brain morphology, blood-brain barrier (BBB) permeability, water content, cytokines such as interferon-γ (IFN-γ), interleukin-10 (IL-10), and chemokine C-X-C ligand 10 (CXCL10), and levels of PD-1 and PD-L1 in the normal control (NC), sham operation, PM, and PD-1 antibody (PM + PD-1 Ab)groups were compared and analyzed. The results showed that streptococcus pneumoniae had multidrug resistance, and the thickness of biofilm decreased with the increase of penicillin minimum inhibitory concentration (MIC). Compared with the NC and Sham groups, BBB permeability, water content, levels of IFN-γ and IL-10, and PD-1 and PD-L1 were signally increased in the PM and PM + PD-1 Ab groups, while CXCL10 level was decreased, exhibiting differences withP<0.05. Based on the PM group, BBB permeability, water content, levels of IFN-γ and CXCL10, and PD-1 and PD-L1 were remarkably decreased in the PM + PD-1 Ab group, while the IL-10 level was observably increased (P<0.05). Therefore, high-MIC penicillin could inhibit the thickness of Streptococcus pneumoniae biofilm, while blocking the PD-1/PD-L1 pathway exerted an improving effect on the PM symptoms.

Anti-dsDNA, anti-nucleosome, anti-C1q, and anti-histone antibodies as markers of active lupus nephritis and systemic lupus erythematosus disease activity.

INTRODUCTION: Previous studies of anti-dsDNA, nucleosome (Nucl), histone (His), and C1q antibodies have revealed their clinical value in systemic lupus erythematosus (SLE). However, the correlation between four autoantibodies and SLE activity, lupus nephritis (LN) remains controversial, and data are insufficient on longitudinal monitoring. This study aimed at evaluating the value of these autoantibodies in active LN, and their performance on cross-sectional evaluating and longitudinal monitoring of SLE disease activity. METHODS: Serum levels of four autoantibodies in 114 SLE patients, 219 other autoimmune disease patients (OAD), and 59 healthy controls were assayed by a quantitative immunoassay. Sera of 38 inpatients were obtained again after treatment. RESULTS: We found that serum levels of four autoantibodies were significantly higher in SLE than OAD patients (p < 001), active LN than non-renal SLE patients (p < .05), and higher in SLE patients with moderate and severe disease activity than mild disease activity (p < .01). Horizontally, serum level of each autoantibody was correlated with SLE disease activity index (SLEDAI) (p < .05), and correlation coefficient of anti-dsDNA was the highest (r = .585). For longitudinal monitoring, the decreased levels of four autoantibodies were found following treatment (p < .001). Serum level variations of these antibodies were positively correlated with variations of SLEDAI (p < .05). The correlation coefficient of anti-Nucl was the highest (r = .629). Although the levels of C3 and C4 increased after treatment, the change was not related to the change of SLEDAI (p > .05). CONCLUSIONS: Anti-C1q, anti-dsDNA, anti-Nucl, and anti-His perform well in diagnosing active LN and monitoring SLE disease activity. They could be indicators of active LN and SLE disease activity.